Microsatellite instability high (MSI-H) cancer represents a distinct group of tumors characterized by defects in DNA repair systems, requiring specialized treatment approaches that differ significantly from other cancer types.

Understanding Treatment Options for Microsatellite Instability Cancer

When someone receives a diagnosis of cancer with high microsatellite instability, the treatment journey begins with understanding what makes this type of cancer different. Microsatellite instability occurs when the body’s normal DNA repair system, called mismatch repair or MMR, stops working properly. This creates unique challenges but also opens doors to specific treatment possibilities that wouldn’t work as well for other cancer types.^[3]

The main goals of treating MSI-high cancers focus on controlling symptoms, slowing how fast the cancer grows, and improving the patient’s quality of life. Treatment decisions depend heavily on several factors, including what stage the cancer has reached, where it’s located in the body, and the patient’s overall health condition. Some patients may have cancer that hasn’t spread beyond its original location, while others face disease that has traveled to distant organs, and these situations call for very different treatment strategies.^[9]

Medical societies and cancer treatment organizations have developed standard treatment guidelines based on years of research and patient outcomes. These approved treatments form the foundation of care that most patients receive. However, the field of cancer medicine continues to evolve rapidly. Researchers constantly work to develop new therapies through clinical trials, testing innovative approaches that might one day become tomorrow’s standard treatments. For patients with MSI-high cancer, this ongoing research has brought particularly exciting developments in recent years, especially in the area of immunotherapy.^[7]

Understanding that microsatellite instability affects approximately 15 to 20 percent of colorectal cancers helps put this condition in perspective. The instability also appears in about one-third of endometrial cancers and smaller percentages of stomach, ovarian, and other cancer types. This makes testing for MSI status an important step in planning treatment, as knowing whether a tumor shows high instability can completely change which medications doctors recommend.^[8]

Standard Treatment Approaches for MSI-High Cancer

Traditional treatment for cancers with high microsatellite instability has historically centered on surgery and chemotherapy, though the effectiveness of these approaches varies significantly compared to cancers without MSI. Surgery remains a cornerstone treatment, especially when the cancer hasn’t spread beyond its original location. Removing the tumor surgically gives many patients the best chance of eliminating the disease, particularly in colorectal cancer where early-stage tumors can often be completely removed.^[3]

Chemotherapy presents a more complicated picture for MSI-high tumors. Research has shown that these cancers respond differently to standard chemotherapy drugs than microsatellite stable tumors do. Specifically, treatment with 5-fluorouracil (5-FU), one of the most common chemotherapy drugs used for colorectal cancer, doesn’t work as well in MSI-high cases. This discovery was crucial because it meant doctors needed to reconsider which medications they prescribed based on a tumor’s MSI status.^[8]

However, when 5-FU is combined with another drug called oxaliplatin in treatment regimens known as FOLFOX, the situation improves. This combination appears to overcome some of the resistance that MSI-high tumors show to 5-FU alone. The oxaliplatin works through a different mechanism, damaging cancer cell DNA in a way that even cells with faulty mismatch repair systems cannot easily fix. Many patients receive this combination therapy either before surgery to shrink tumors or after surgery to eliminate any remaining cancer cells.^[8]

Radiation therapy may also play a role in treatment, particularly for rectal cancers. High-energy beams target cancer cells, damaging their DNA and preventing them from multiplying. Doctors sometimes use radiation before surgery to shrink tumors, making them easier to remove completely. The duration of radiation treatment typically spans several weeks, with patients receiving treatment five days per week. Side effects can include fatigue, skin irritation in the treated area, and digestive problems if the radiation affects the bowel.

The duration of standard chemotherapy treatment varies considerably. Patients who receive chemotherapy after surgery to prevent cancer recurrence typically continue treatment for approximately six months. Those with advanced cancer that has spread to other organs may receive chemotherapy for longer periods, sometimes continuing until the treatment stops working or side effects become too severe. Common side effects of chemotherapy include nausea, fatigue, hair loss, increased infection risk due to lowered blood cell counts, and nerve damage that causes tingling or numbness in hands and feet.

Immunotherapy: A Breakthrough for MSI-High Cancer Treatment

The discovery that MSI-high cancers respond remarkably well to immunotherapy represents one of the most significant advances in cancer treatment in recent decades. Immunotherapy works by helping the patient’s own immune system recognize and attack cancer cells. This approach differs fundamentally from chemotherapy, which directly poisons cancer cells, or surgery, which physically removes them.^[9]

The reason immunotherapy works so well for MSI-high cancers relates directly to what makes these tumors different at the molecular level. When the mismatch repair system fails, cancer cells accumulate many more DNA mutations than normal. These mutations create abnormal proteins called neoantigens that appear on the cancer cell surface. The immune system can recognize these neoantigens as foreign, similar to how it identifies bacteria or viruses. However, cancer cells often develop ways to hide from immune attack by using molecular “brake” signals that shut down immune responses.^[9]

The most successful immunotherapy drugs for MSI-high cancer are called checkpoint inhibitors. These medications work by releasing the brakes that cancer cells put on the immune system. The primary targets are proteins called PD-1, PD-L1, and CTLA-4. When checkpoint inhibitor drugs block these proteins, immune cells called T-cells can once again recognize and destroy cancer cells.^[13]

Pembrolizumab (brand name Keytruda) became the first drug approved specifically for treating MSI-high cancers regardless of where in the body the cancer originated. This approval by the FDA represented a historic moment because it was the first time a cancer drug was approved based on a tumor’s genetic characteristics rather than which organ the cancer started in. Pembrolizumab blocks the PD-1 protein on immune cells, allowing them to attack cancer. Patients typically receive this medication through an intravenous infusion every three to six weeks, and treatment may continue for up to two years or until the cancer progresses.^[7]

Nivolumab (brand name Opdivo) is another PD-1 inhibitor approved for treating MSI-high colorectal cancer that has spread to other parts of the body. This drug works through the same mechanism as pembrolizumab, blocking PD-1 to unleash immune responses against cancer. Clinical trials have shown that nivolumab can shrink tumors in a significant percentage of patients with MSI-high colorectal cancer who had previously tried chemotherapy without success. The treatment is administered through intravenous infusion, typically every two weeks.^[9]

Researchers have also explored combining different checkpoint inhibitors to achieve even better results. One particularly promising combination pairs nivolumab with ipilimumab (brand name Yervoy). Ipilimumab targets a different checkpoint protein called CTLA-4. By blocking both PD-1 and CTLA-4 simultaneously, this combination attacks cancer through two different pathways, potentially overcoming resistance mechanisms that might develop with single-agent therapy. Clinical trials have demonstrated that this combination can produce responses in patients whose cancer had stopped responding to other treatments.^[9]

Side effects from immunotherapy differ from those of chemotherapy because these drugs work by activating rather than suppressing the immune system. The most common side effects relate to the immune system becoming overactive and attacking normal body tissues. Patients may experience fatigue, skin rashes, diarrhea, or inflammation of organs like the lungs, liver, or thyroid gland. These side effects, called immune-related adverse events, can range from mild to severe. Most patients tolerate immunotherapy better than chemotherapy, but serious side effects do occur and require careful monitoring. Doctors often treat significant immune-related side effects with corticosteroids to calm the overactive immune response.

The duration of immunotherapy treatment varies. Some patients continue treatment for a fixed period, such as two years, while others may continue as long as the treatment keeps working and side effects remain manageable. Remarkably, some patients experience continued cancer control even after stopping immunotherapy, as the immune system appears to maintain its ability to fight the cancer.

Innovative Therapies Being Tested in Clinical Trials

Beyond the immunotherapy drugs already approved, researchers continue developing and testing new treatment approaches for MSI-high cancers through clinical trials conducted around the world, including in the United States, Europe, and other regions. These studies explore novel ways to help the immune system fight cancer more effectively or target specific weaknesses in MSI-high tumor cells.

One area of active investigation involves targeting an enzyme called WRN. Scientists recently discovered that cancer cells with microsatellite instability depend heavily on this enzyme to survive, while normal cells and microsatellite stable cancer cells do not. When researchers experimentally removed WRN from MSI-high cancer cells in the laboratory, the cells’ DNA literally shattered, killing them. This happens because MSI-high cells contain unusually long stretches of repeated DNA sequences that form unusual structures. WRN normally helps untangle these structures, but without it, the repeated sequences cause catastrophic DNA breaks. Several pharmaceutical companies are now racing to develop drugs that specifically inhibit WRN, hoping to create new treatments that would kill MSI-high cancer cells while sparing normal tissues.^[14]

Clinical trial phases help determine whether new treatments are safe and effective. Phase I trials focus primarily on safety, testing new drugs in small groups of patients to determine the highest dose that can be given without causing unacceptable side effects. These trials enroll patients whose cancer has not responded to standard treatments. Phase I trials also provide the first glimpses of whether a new drug might work against cancer.^[7]

Phase II trials expand testing to larger patient groups to evaluate how well the treatment works against specific cancer types. These studies carefully measure how many patients’ tumors shrink, how long responses last, and what percentage of patients experience different side effects. Phase II trials often focus on specific cancer types or biomarker groups, such as MSI-high tumors. If results look promising, the drug advances to Phase III testing.

Phase III trials represent the final step before potential drug approval. These large studies compare the new treatment against current standard therapy in hundreds or sometimes thousands of patients. Only if the new treatment proves superior—either by helping patients live longer, improving quality of life, or causing fewer side effects—will regulatory agencies like the FDA consider approving it for general use.

Several novel immunotherapy combinations are currently being studied specifically for MSI-high cancers. Researchers are testing whether adding other types of immune-stimulating drugs to checkpoint inhibitors can help more patients respond to treatment. Some trials explore combining immunotherapy with targeted drugs that interfere with specific growth signals cancer cells use to multiply. The goal is to attack cancer through multiple mechanisms simultaneously, potentially overcoming resistance.

Another innovative approach being tested involves cancer vaccines. Unlike vaccines that prevent infections, cancer vaccines aim to teach the immune system to recognize and attack cancer cells. For MSI-high cancers, which produce many abnormal proteins due to their high mutation rate, researchers are developing personalized vaccines tailored to each patient’s specific tumor mutations. These vaccines would train the patient’s immune system to recognize the unique neoantigens present in their cancer, potentially creating a more powerful and targeted immune response than checkpoint inhibitors alone can achieve.

Eligibility for clinical trials typically requires that patients meet specific criteria. Doctors assess factors including the type and stage of cancer, previous treatments received, overall health status, and whether the tumor shows certain biomarkers like MSI-high status. Patients interested in clinical trials should discuss options with their oncologist, who can help determine whether any available trials might be appropriate. Clinical trial databases maintained by organizations like the National Cancer Institute provide searchable listings of ongoing studies, including information about locations, eligibility requirements, and how to enroll.

Detecting Microsatellite Instability: Testing Methods

Determining whether a cancer has high microsatellite instability requires specialized laboratory testing performed on tumor tissue. Doctors typically obtain this tissue through a biopsy, where a small sample of the tumor is removed for analysis. The testing can be done on tissue from the primary tumor or from cancer that has spread to other locations.^[7]

Two main approaches exist for detecting MSI. The first method, called immunohistochemistry (IHC), examines whether mismatch repair proteins are present in tumor cells. The four main proteins evaluated are MLH1, MSH2, MSH6, and PMS2. In normal cells and most cancers, all four proteins are present. When one or more of these proteins is missing, the tumor is classified as mismatch repair deficient (dMMR), which essentially means the same thing as MSI-high. Immunohistochemistry testing is relatively quick and widely available in pathology laboratories.^[8]

The second approach uses molecular testing techniques to directly examine specific DNA sequences called microsatellites. Laboratories compare the length of these repeated DNA sequences in tumor tissue versus normal tissue from the same patient. If many microsatellites show length differences, the tumor is classified as MSI-high. If few or no microsatellites show changes, the tumor is microsatellite stable (MSS) or MSI-low. Advanced techniques like next-generation sequencing can detect microsatellite instability while simultaneously analyzing hundreds of other genes for mutations, providing comprehensive genetic information about the tumor.^[7]

Medical guidelines now recommend that all patients with colorectal cancer and endometrial cancer undergo testing for microsatellite instability or mismatch repair deficiency. This recommendation exists not only to guide treatment decisions but also to identify patients who might have Lynch syndrome, an inherited condition that increases cancer risk. About 5 percent of MSI-high colorectal cancers occur in people with Lynch syndrome, who inherited a mutated copy of a mismatch repair gene from a parent. Identifying Lynch syndrome has important implications for the patient’s family members, who may also carry the mutation and benefit from increased cancer screening.^[3]

Most Common Treatment Methods

• Immunotherapy with Checkpoint Inhibitors
  • Pembrolizumab (Keytruda), a PD-1 blocking drug approved for MSI-high cancers regardless of tumor location
  • Nivolumab (Opdivo), another PD-1 inhibitor used for MSI-high colorectal cancer
  • Combination of nivolumab plus ipilimumab (Yervoy), targeting both PD-1 and CTLA-4 pathways
  • Treatment delivered through intravenous infusion every two to six weeks
  • May continue for up to two years or until disease progression
• Surgery
  • Complete removal of tumor when cancer is localized
  • Primary treatment option for early-stage disease
  • May be preceded by chemotherapy or radiation to shrink tumors
• Chemotherapy
  • FOLFOX regimen combining 5-fluorouracil and oxaliplatin for better effectiveness in MSI-high tumors
  • Typically administered for six months after surgery to prevent recurrence
  • May continue longer for advanced or metastatic disease
  • Less effective as single agents compared to microsatellite stable cancers
• Radiation Therapy
  • Used primarily for rectal cancer before surgery
  • Treatment typically spans several weeks with daily sessions
  • Helps shrink tumors to make surgical removal more complete
• Experimental Therapies in Clinical Trials
  • WRN enzyme inhibitors being developed to target specific vulnerability of MSI-high cells
  • Personalized cancer vaccines designed to train immune system against tumor-specific mutations
  • Novel immunotherapy combinations testing new ways to enhance immune response
  • Available at major cancer centers in the United States, Europe, and other regions